These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38462072)

  • 1. Drugs associated with serum sickness and serum sickness-like reactions: A review of FDA Adverse Event Reporting System (FAERS) data.
    Surdacki M; Fernandez E; Phillips EJ; Stone CA
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1351-1354.e1. PubMed ID: 38462072
    [No Abstract]   [Full Text] [Related]  

  • 2. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
    Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
    Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
    Zhou Z; Hultgren KE
    JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of Information on Drug Adverse Reactions Using U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)].
    Nango D; Sekizuka T; Goto M; Echizen H
    Yakugaku Zasshi; 2022; 142(4):341-344. PubMed ID: 35370189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System.
    Iyer G; Marimuthu SP; Segal JB; Singh S
    Drug Saf; 2017 Sep; 40(9):799-808. PubMed ID: 28593504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter to the editor concerning the article: 'Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)'.
    Sinvhal R; Krueger WS; Kilpatrick RD; Coppola D
    Br J Clin Pharmacol; 2023 Aug; 89(8):2639-2641. PubMed ID: 37114281
    [No Abstract]   [Full Text] [Related]  

  • 9. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS).
    Yu RJ; Krantz MS; Phillips EJ; Stone CA
    J Allergy Clin Immunol Pract; 2021 Feb; 9(2):819-829.e2. PubMed ID: 32992044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection.
    Xu R; Wang Q
    BMC Bioinformatics; 2014 Jan; 15():17. PubMed ID: 24428898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
    Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
    Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).
    Xu R; Wang Q
    J Biomed Inform; 2014 Feb; 47():171-7. PubMed ID: 24177320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Alatawi YM; Hansen RA
    Expert Opin Drug Saf; 2017 Jul; 16(7):761-767. PubMed ID: 28447485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases].
    Sasaoka S; Matsui T; Abe J; Umetsu R; Kato Y; Ueda N; Hane Y; Motooka Y; Hatahira H; Kinosada Y; Nakamura M
    Yakugaku Zasshi; 2016; 136(3):507-15. PubMed ID: 26935094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
    Nagai J; Ishikawa Y
    PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
    Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
    Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System.
    Serebruany VL; Hall TS; Atar D; Agewall S; Hyun Kim M; Geudelin B; Lomakin N; Marciniak TA
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):210-215. PubMed ID: 30192939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.